Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation

NCT ID: NCT01749579

Last Updated: 2012-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sixty patients who refer to the emergency ward and need any painful procedure in the ward are randomized into 2 groups. One group is sedated before the procedure using propofol-fentanyl and the other with midazolam-fentanyl, with the same depth of sedation. The two groups will be compared regarding recovery time and other parameters described below.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emergencies

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

propofol midazolam duration of recovery emergency procedure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Propofol

The patients will receive propofol for sedation in addition to fentanyl

Group Type EXPERIMENTAL

Propofol

Intervention Type DRUG

Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3

Fentanyl

Intervention Type DRUG

Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure

Midazolam

The patients will receive midazolam for sedation in addition to fentanyl

Group Type ACTIVE_COMPARATOR

Midazolam

Intervention Type DRUG

Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.

Fentanyl

Intervention Type DRUG

Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol

Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3

Intervention Type DRUG

Midazolam

Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.

Intervention Type DRUG

Fentanyl

Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age more than 18
* candidate for a painful procedure
* negative past history of a serious medical condition
* ASA score 0 and 1

Exclusion Criteria

* deep sedation making the patient unable to answer the questions
* pregnancy
* allergy to drugs
* hemodynamic instability
* failure to consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tehran University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohammad Jalili, MD

Role: STUDY_CHAIR

Tehran University of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imam Khomeini Hospital

Tehran, Tehran Province, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammad Jalili, MD

Role: CONTACT

Phone: +98(912)5483998

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

130-2640

Identifier Type: -

Identifier Source: org_study_id